Mourad Tayebi, PhD, Western Sydney University, Penrith, Australia, explains the current outlook of the field of immunotherapy in Alzheimer’s disease. In the past, a lack of understanding led to a hit-and-miss approach to drug development. However, advancements in bioinformatics can now support a systematized approach, informing us of the types of epitope that can be used to generate non-toxic and non-allergenic antibodies. While a lack of rigorous characterization of putative therapeutic antibodies has led to setbacks, the knowledge gained is informing current studies. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
